News
BRRGF
1.770
NaN%
--
Oncoinvent bolsters Radspherin programme with Phase 2 progress and NOK 148.5m raise
TipRanks · 2h ago
Oncoinvent sets investor webcast as it advances radiopharmaceutical cancer therapy
TipRanks · 10/20 05:37
Oncoinvent Cancels Planned Subsequent Share Offering After Price Slump
TipRanks · 10/08 08:08
Oncoinvent Completes Private Placement as Linc AB Stake Rises to 12.21%
TipRanks · 10/02 08:07
Hadean Ventures Funds Lift Oncoinvent Stake to Over 12% After Private Placement
TipRanks · 09/30 14:37
Oncoinvent Registers Share Capital Increase After Private Placement
TipRanks · 09/30 09:03
Oncoinvent’s Radspherin Program Gains Spotlight at EANM and ESMO 2026
TipRanks · 09/30 05:39
Oncoinvent Details Insider Allocation in Retail Share Offering
TipRanks · 09/23 08:32
Oncoinvent Shares Begin Trading Ex-Rights Ahead of Planned Offering
TipRanks · 09/23 05:37
Hadean Ventures Funds Adjust Oncoinvent Stake Amid Private Placement Settlement
TipRanks · 09/22 23:32
Oncoinvent Publishes Insider Allocation Details from Recent Private Placement
TipRanks · 09/22 23:02
Oncoinvent Sets Terms for Conditional Repair Offering After Private Placement
TipRanks · 09/22 22:32
Oncoinvent Raises NOK 148.5 Million to Advance Radspherin Into Late-Stage Trials
TipRanks · 09/22 22:09
Oncoinvent Seeks NOK 140 Million to Bolster Ovarian Cancer Trial and Phase 3 Plans
TipRanks · 09/22 15:07
Oncoinvent Asa Earnings Call Highlights Trial Momentum
TipRanks · 08/30 00:25
Oncoinvent advances Radspherin trials and IP as losses widen in first half 2026
TipRanks · 08/27 05:46
Oncoinvent Sets August Webcast as Radspherin Advances Toward Post-Surgical Cancer Standard
TipRanks · 08/17 05:38
Oncoinvent’s Radspherin Shows Favorable Dosimetry in Phase 1 Cancer Studies
TipRanks · 08/11 05:40
Oncoinvent Aligns Board Incentives with Equity Grants as Radspherin Advances
TipRanks · 05/20 19:02
Oncoinvent Clears AGM Agenda as It Pushes Radspherin Toward Post-Surgical Cancer Market
TipRanks · 05/20 09:35
More
Webull provides a variety of real-time BRRGF stock news. You can receive the latest news about Oncoinvent ASA through multiple platforms. This information may help you make smarter investment decisions.
About BRRGF
Oncoinvent ASA, formerly Bergenbio ASA, is a Norway-based clinical-stage biopharmaceutical company focused on developing drugs for aggressive diseases including cancer and severe respiratory infections. The Company's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The Company's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. The Company is based in Bergen, Norway with a subsidiary in Oxford, UK.